UNSPSC 51142415: Combination acetaminophen butalbital

This classification denotes a combination drug that treats migraines. The first component of this drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but generally known as acetaminophen (or paracetamol), which bears US NIH Compound Identifier 1983.

Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. European Medicines Agency schedules Acetaminophen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG. World Health Organization schedules acetaminophen in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: OC1CCC(NC(=O)C)CC1.

UNSPSC 51142415 Combination acetaminophen butalbital (Commodity) encompasses pharmaceutical products that state and local governments procure through health departments, emergency response programs, and cooperative purchasing consortiums. Recent opportunities show that state and local buyers under this code are actually sourcing naloxone kits, over-the-counter pain relievers, generic multi-source pharmaceuticals, and drug deactivation systems—products spanning emergency medical response, community health initiatives, and pharmacy benefit programs. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions. Procurement follows standard state and local channels: competitive sealed bidding (IFB), requests for proposal (RFP), and requests for information (RFI) as preliminary market-intelligence phases before formal solicitation.

Recent activity clusters in Florida and Texas, with significant multistate reach through cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with responses due July 26, 2023, and quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state movement toward direct pharmacy contracting models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with responses due March 26, 2026, and contract awards effective July 1, 2026. Vendors must hold cGMP certification, comply with the Drug Supply Chain Security Act, maintain wholesaler relationships, and meet substantial insurance requirements including $5,000,000 commercial general liability per occurrence.